Kymera Therapeutics Inc(KYMR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.24 | Insider Own | 10.18% | Shs Outstand | 82.8M | Perf Week | 5.71% |
| Market Cap | 9.21B | Forward P/E | - | EPS next Y | -32.31% | Insider Trans | -30.3% | Shs Float | 74.7M | Perf Month | -4.36% |
| Enterprise Value | 8.60B | PEG | - | EPS next Q | -1.27 | Inst Own | 108.96% | Short Float | 13.27% | Perf Quarter | 0.65% |
| Income | -0.30B | P/S | 87.71 | EPS this Y | -4.51% | Inst Trans | 0.91% | Short Ratio | 13.42 | Perf Half Y | 30.44% |
| Sales | 0.10B | P/B | 6.08 | EPS next 5Y | -14.44% | ROA | -21.58% | Short Interest | 9.91M | Perf YTD | 42.35% |
| Book/sh | 18.23 | P/C | 13.33 | EPS past 3/5Y | -8.68% -3.19% | ROE | -24.15% | 52W High | -14.83% ($130.05) | Perf Year | 91.76% |
| Cash/sh | 8.31 | P/FCF | - | Sales past 3/5Y | -5.74% 2.87% | ROIC | -19.03% | 52W Low | 100.43% ($55.26) | Perf 3Y | 829.19% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 6.73% | Gross Margin | 92.16% | Volatility(W/M) | 3.76% 4.76% | Perf 5Y | 98.92% |
| Dividend TTM | - | EV/Sales | 81.88 | Sales Y/Y TTM | 134.84% | Oper. Margin | -329.83% | ATR (14) | 4.92 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 10.34 | EPS Q/Q | 34.53% | Profit Margin | -285.34% | RSI (14) | 49.24 | Recom | 1.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.34 | Sales Q/Q | 466.4% | SMA20 | 1.06% ($109.6) | Beta | 2.06 | Target Price | $139.35 |
| Payout | - | Debt/Eq | 0.05 | Earnings | 2026/8/5 | SMA50 | -3.7% ($115.02) | Rel Volume | 0.7 | Prev Close | $110.85 |
| Employees | 238 | LT Debt/Eq | 0.04 | EPS/Sales Surpr. | 12.99% 98.32% | SMA200 | 16.27% ($95.26) | Avg Volume(3M) | 0.74M | Price | $110.76 |
| IPO | 2020/8/21 | Option/Short | Yes/Yes | Trades | 9363 | Volume | 517,065 | Change | -0.08% |
A clinical-stage biotech company developing new drugs using targeted protein degradation technology. It develops oral therapies that degrade and eliminate disease-causing proteins, targeting immune/inflammatory diseases and oncology. This is a bio-healthcare stock whose share price is largely driven by late-stage clinical progress and funding conditions.
Over the past 1 year, roughly in the middle
15% below its 1-year high.
Traded less than usual. That is 70% of its average volume.
KYMR has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -4.5% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $8,771. Peers typically go for $1,510. Compared with its own 5-year average, it is 58% pricier now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +98.9%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 109.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #27 of 595 in the industry
Based on market cap of $9B.
CORT#24 Corcept Therapeutics Inc $9B PER 205.1 
KRYS#25 Krystal Biotech Inc $9B PER 39.0 
TWST#26 Twist Bioscience Corp $9B PER - KYMR#27 Kymera Therapeutics Inc $9B PER - 
CAI#28 Caris Life Sciences Inc $9B PER 86.0 
FAQ
What kind of company is KYMR?
KYMR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of KYMR?
The market cap of KYMR is approximately $9.2B, ranking 968 within its sector.
What is the 52-week high and low for KYMR?
KYMR has recorded a 52-week high of $130.05 and a low of $55.26.
